Fibrin chain cross-linking, fibrinolysis, and in vivo sealing efficacy of differently structured fibrin sealants

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 100 B, Issue 6, 2012, Pages 1507-1512

  Hedrich, Hans Christian ^a   Simunek, Manuela ^a   Reisinger, Sonja ^a   Ferguson, James ^b   Gulle, Heinz ^a   Goppelt, Andreas ^a   Redl, Heinz ^b  

^a BAXTER INNOVATIONS GMBH   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

animal model; clot lysis; fibrin; sealing; wound healing

Indexed keywords

ANIMAL MODEL; APROTININ; CLOT LYSIS; FIBRIN; FIBRIN SEALANTS; IN-VITRO; IN-VIVO; WOUND HEALING;

ANIMALS; SEALING (FINISHING);

SEALANTS;

APROTININ; FIBRIN GLUE;

ANIMAL EXPERIMENT; ARTICLE; CROSS LINKING; DRUG EFFECT; FIBRINOLYSIS; NONHUMAN; RABBIT; ULTRASTRUCTURE;

ANIMALS; APROTININ; FIBRIN; FIBRIN TISSUE ADHESIVE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; MATERIALS TESTING; PLASMINOGEN; RABBITS; SERINE PROTEINASE INHIBITORS; TISSUE ADHESIVES;

EID: 84863726534     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.32719     Document Type: Article

References (14)

1. Schlag MG, Schlag MG, Hopf R, Zifko U, Redl H,. Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats. Acta Neurochir 2002; 144: 63-69.
2. Furtmuller R, Schlag MG, Berger M, Hopf R, Huck S, Sieghart W, Redl H,. Tranexamic acid, a widely used antifibrinolytic agent, causes convulsions by a g-aminobutyric acid(A) receptor antagonistic effect. J Pharmacol Exp Ther 2002; 301: 168-173.
3. Fürst W, Banerjee A, Redl H,. Comparison of structure, strength and cytocompatibility of a fibrin matrix supplemented either with tranexamic acid or aprotinin. J Biomed Mater Res Part B: Appl Biomater 2006; 82B: 109-114.
4. Henry D, Carless P, Fergusson D, Laupacis A,. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 9; 180: 183-193.
5. Tse DC, Mankarious SS, Liu SL, Thomas, WR, Alpern M, Enomoto ST, Garanchon CM, US Patent 5,792,835, 1998
6. Hickerson WL, Nur I, Meidler R,. A comparison of the mechanical, kinetic, and biochemical properties of fibrin clots formed with two different fibrin sealants. Blood Coagulat Fibrinol 2011; 22: 19-23.
7. Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW,. Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis. Arteroscler Thromb Vasc Biol 2000; 20: 1354-1361.
8. Isaacs JE, McDaniel CO, Owen JR, Wayne JS,. Comparative analysis of biomechanical performance of available nerve glues. J Hand Surg 2008; 33A: 893-899
9. Gaffney PJ, Whitaker AN,. Fibrin crosslinks and lysis rates. Thromb Res 1979; 14: 85-94
10. McDonagh RP, McDonagh J, Duckert F,. The influence of fibrin crosslinking on the kinetics of urokinase-induced clot lysis. Br J Haematol 1971; 21: 323-332
11. Loscalzo J, Schafer AI,. Thrombosis and Hemorrhage, 3rd ed. Philadelphia: Lippincott Williams and Wilkins, 2003.
12. Ariens RA, Lai TS, Weisel JW, Greenberg CS, Grant PJ,. Role of factor XIII in fibrin clot formation and effects of genetic polymorphisms. Blood 2002; 100: 743-754.
13. Buchta C, Hedrich HC, Macher M, Höcker P, Redl H,. Biochemical characterization of autologous fibrin sealants produced by Cryoseal and Vivostat in comparison to the homologous fibrin sealant product Tissucol/TisseeÂ. Biomaterials 2005; 26: 6233-6241.
14. Collen D, Lijnen HR,. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-3124.